Research Conversations: Better Treatments for Metastatic Prostate Cancer
Medical oncologist and PCF-funded Young Investigator Dr. Martin Schoen discusses a recent publication supported by his 2022 Young Investigator Award. Combination therapy refers to adding another medicine (an androgen receptor pathway inhibitor [ARPI] or chemotherapy) to standard hormone therapy.
- Use of combination therapy for metastatic prostate cancer has increased over the past decade
- Combination therapy with an ARPI is more effective than hormone therapy alone, decreasing the risk of death by 20%
- Dr. Schoen notes that patients with prostate cancer that has spread to bones or other locations should discuss the benefits of combination therapy with their doctor